Faris Farassati
Overview
Explore the profile of Faris Farassati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dolatkhah R, Somi M, Dastgiri S, Jafarabadi M, Sepehri B, Shirmohammadi M, et al.
Ecancermedicalscience
. 2022 May;
16:1354.
PMID: 35510134
Background: Colorectal cancer (CRC) is the third most common cancer and the second leading cause of death worldwide. However, CRC is considered as one of the most preventable cancers by...
2.
Dolatkhah R, Somi M, Dastgiri S, Jafarabadi M, Mashhadi Abdolahi H, Shanehbandi D, et al.
Ann Med Surg (Lond)
. 2022 Mar;
76:103494.
PMID: 35345791
Background: Globally, colorectal cancer (CRC) is the third most common cancer and the second leading cause of death from cancer. Incidence and mortality from CRCboth can be reduced and prevented...
3.
Dolatkhah R, Dastgiri S, Eftekhar Sadat A, Farassati F, Nezamdoust M, Somi M
Bioimpacts
. 2021 Jan;
11(1):5-14.
PMID: 33469503
Early-activated mutation status is a key molecular finding in colorectal cancer (CRC), while these mutations have been proposed as predictive and prognostic biomarkers. The present study has been designed as...
4.
Hosseini M, Farassati F, Farassati F
Onco Targets Ther
. 2020 Oct;
13:9349-9350.
PMID: 33061422
No abstract available.
5.
Dolatkhah R, Somi M, Shabanloei R, Farassati F, Fakhari A, Dastgiri S
Asian Pac J Cancer Prev
. 2018 Aug;
19(8):2183-2190.
PMID: 30139223
Objective: Although several factors have been shown to have etiological roles in colorectal cancer, few investigations
have addressed how and to what extent these factors affect the genetics and pathology...
6.
Terai K, Bi D, Liu Z, Kimura K, Sanaat Z, Dolatkhah R, et al.
Stem Cells
. 2018 Apr;
36(8):1154-1169.
PMID: 29658163
The topic of cancer stem cells (CSCs) is of significant importance due to its implications in our understanding of the tumor biology as well as the development of novel cancer...
7.
Patrad E, Niapour A, Farassati F, Amani M
Cytotechnology
. 2018 Feb;
70(2):865-877.
PMID: 29417442
Current medication for gastric cancer patients has a low success rate with resistance and side effects. According to recent studies, γ-secretase inhibitors is used as therapeutic drugs in cancer. Moreover,...
8.
Boostani F, Dolatkhah R, Fakhrjou A, Farassati F, Sanaat Z
Onco Targets Ther
. 2018 Feb;
11:449-457.
PMID: 29403289
Background: Recently, it was found that the overexpression and mutation status of affect cancer progression and patient outcome in several human tumors. We aimed to evaluate the clinicopathologic significance of...
9.
Shabbir A, Esfandyari T, Farassati F
Onco Targets Ther
. 2018 Jan;
11:183-184.
PMID: 29379299
No abstract available.
10.
Moghadam A, Patrad E, Tafsiri E, Peng W, Fangman B, Pluard T, et al.
Cancer Med
. 2017 Oct;
6(12):2998-3013.
PMID: 29047224
The Ral (Ras-Like) signaling pathway plays an important role in the biology of cells. A plethora of effects is regulated by this signaling pathway and its prooncogenic effectors. Our team...